{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:20:17Z","timestamp":1772666417735,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4069-1","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:03:22Z","timestamp":1558699402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance"],"prefix":"10.1186","volume":"19","author":[{"given":"Ammar Ali Saleh","family":"Jaber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baharudin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"4069_CR1","unstructured":"World Health Organization: companion handbook to the WHO guidelines for the programmatic management of drug-resistance tuberculosis. \n                    https:\/\/www.who.int\/tb\/publications\/pmdt_companionhandbook\/en\/\n                    \n                   (2014). Accessed 08 May 2018."},{"key":"4069_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.5588\/ijtld.15.0167","volume":"19","author":"N Ahmad","year":"2015","unstructured":"Ahmad N, Javaid A, Basit A, Afridi AK, Khan MA, Ahmad I, et al. Management and treatment outcomes of MMDR-TB: results from a setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19:1109\u201314.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR3","unstructured":"National Tuberculosis Control Programme: treatment of tuberculosis guidelines. (2010). Accessed 09 Apr 2018."},{"key":"4069_CR4","unstructured":"World Health Organization: Guideline on management of drug resistance-TB. In: WHO treatment guidelines for drug-resistant tuberculosis. (2016). Accessed 06 Apr 2018."},{"key":"4069_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/14787210.2018.1519393","volume":"16","author":"S Ahmad","year":"2018","unstructured":"Ahmad S, Mokaddas E, Al-Mutairi NM. Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East region. Expert Rev Anti-Infect Ther. 2018;16:709\u201321.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"4069_CR6","first-page":"1328","volume":"11","author":"A Al-Akhali","year":"2007","unstructured":"Al-Akhali A, Ohkado A, Fujiki A, Mitarai S, Yamada N, Masui T, et al. Nationwide survey on the prevalence of anti-tuberculosis drug resistance in the Republic of Yemen, 2004. Int J Tuberc Lung Dis. 2007;11:1328\u201333.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4069_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijmyco.2016.08.008","volume":"5","author":"MM Ahmed","year":"2016","unstructured":"Ahmed MM, Velayati AA, Mohammed SH. Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in Middle East countries. Int J Mycobacteriol. 2016;5:249\u201356.","journal-title":"Int J Mycobacteriol"},{"key":"4069_CR8","first-page":"479","volume":"194","author":"M Zignol","year":"2006","unstructured":"Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Invest Dermatol. 2006;194:479\u201385.","journal-title":"J Invest Dermatol"},{"key":"4069_CR9","unstructured":"National Tuberculosis Control Programme: Guideline on management of drug resistance-TB Yemen. (2012). Accessed 02 Nov 2018."},{"key":"4069_CR10","first-page":"496","volume":"4","author":"CBE Chee","year":"2000","unstructured":"Chee CBE, Boudville IC, Chan SP, Zee YK, Wang YT. Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit\u2014a one-year retrospective survey. Int J Tuberc Lung Dis. 2000;4:496\u2013503.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra0908076","volume":"363","author":"E Nathanson","year":"2010","unstructured":"Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, L\u00f6nnroth K, et al. MDR tuberculosis\u2014critical steps for prevention and control. N Engl J Med. 2010;363:1050\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"4069_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000348374","volume":"86","author":"YA Kang","year":"2014","unstructured":"Kang YA, Kim SY, Jo KW, Kim HJ, Park SK, Kim TH, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration. 2014;86(6):472\u20138.","journal-title":"Respiration."},{"key":"4069_CR13","unstructured":"World Health Organization: Global tuberculosis report 2016. (2016). Accessed 12 Jan 2016."},{"key":"4069_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5588\/ijtld.12.0481","volume":"17","author":"M Rodriguez","year":"2013","unstructured":"Rodriguez M, Monedero I, Caminero JA, Encarnaci\u00f3n M, Dominguez Y, Acosta I, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17:520\u20135.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR15","first-page":"402","volume":"10","author":"SS Shin","year":"2006","unstructured":"Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MMDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402\u20138.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR16","unstructured":"World Health Organization: Strategic plan for the prevention and control of multidrug-resistant and extensively drug-resistant tuberculosis in the Eastern Mediterranean Region (2010\u20132015). (2010). Accessed 23 July 2018."},{"key":"4069_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1183\/09031936.00155708","volume":"33","author":"K Kliiman","year":"2009","unstructured":"Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33:1085\u201394.","journal-title":"Eur Respir J"},{"key":"4069_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1378\/chest.117.3.744","volume":"117","author":"WW Yew","year":"2000","unstructured":"Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin\/levofloxacin-containing regimens. Chest. 2000;117:744\u201351.","journal-title":"Chest."},{"key":"4069_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/annotation\/032b026d-5bcf-4c1b-aa15-65c226a53818","volume":"8","author":"S Tang","year":"2013","unstructured":"Tang S, Tan S, Yao L, Li F, Guo X, Liu Y, et al. Risk factors for poor treatment outcomes in patients with MMDR-TB and XMDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8:1\u20138.","journal-title":"PLoS One"},{"key":"4069_CR20","doi-asserted-by":"publisher","first-page":"e6914","DOI":"10.1371\/journal.pone.0006914","volume":"4","author":"JC Johnston","year":"2009","unstructured":"Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914.","journal-title":"PLoS One"},{"key":"4069_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jphs.12196","volume":"9","author":"A Ali","year":"2018","unstructured":"Ali A, Jaber S. Evaluation of tuberculosis defaulters in Yemen from the perspective of health care service. J Pharm Health Serv Res. 2018;9:1\u201312.","journal-title":"J Pharm Health Serv Res"},{"key":"4069_CR22","doi-asserted-by":"publisher","first-page":"e0156258","DOI":"10.1371\/journal.pone.0156258","volume":"11","author":"AAS Jaber","year":"2016","unstructured":"Jaber AAS, Khan AH, Sulaiman SAS, Ahmad N, Anaam MS. Evaluation of health-related quality of life among tuberculosis patients in two cities in Yemen. PLoS One. 2016;11:e0156258.","journal-title":"PLoS One"},{"key":"4069_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40545-017-0124-8","volume":"10","author":"AAS Jaber","year":"2017","unstructured":"Jaber AAS, Khan AH, Sulaiman SAS. Evaluating treatment outcomes and durations among cases of smear-positive pulmonary tuberculosis in Yemen: a prospective follow-up study. J Pharm Policy Pract. 2017;10:36.","journal-title":"J Pharm Policy Pract"},{"key":"4069_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tube.2012.06.003","volume":"92","author":"EV Kurbatova","year":"2012","unstructured":"Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92:397\u2013403.","journal-title":"Tuberculosis."},{"key":"4069_CR25","first-page":"750","volume":"12","author":"MR Masjedi","year":"2008","unstructured":"Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, et al. Outcome of treatment of MMDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis. 2008;12:750\u20135.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR26","first-page":"275","volume":"14","author":"E Bloss","year":"2010","unstructured":"Bloss E, Kuk\u0161a L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000\u20132004. Int J Tuberc Lung Dis. 2010;14:275\u201381.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR27","doi-asserted-by":"publisher","first-page":"e1126","DOI":"10.1371\/journal.pone.0001126","volume":"2","author":"HS Cox","year":"2007","unstructured":"Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, R\u00fcsch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XMDR-TB among treatment failures. PLoS One. 2007;2:e1126.","journal-title":"PLoS One"},{"key":"4069_CR28","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.5588\/ijtld.10.0679","volume":"15","author":"F Qazi","year":"2011","unstructured":"Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, Salahuddin N, et al. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis. 2011;15:1556\u20139.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4069_CR29","first-page":"58","volume":"7","author":"R Singla","year":"2003","unstructured":"Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis. 2003;7:58\u201364.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4069_CR30","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/cid\/ciu619","volume":"59","author":"ML Bastos","year":"2014","unstructured":"Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014;59:1364\u201374.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4069-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:08:09Z","timestamp":1590188889000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4069-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4069"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4069-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Although the study did not include human samples, patient cards and records were reviewed for data collection. Therefore, consent for participation was designed by the investigators and approved by the ethical committee of the college. Ethical approval for this study was also obtained from the National Committee of Health, Ministry of Health (Sana\u2019a, Yemen) and the NTCP. In addition, a collaboration letter was obtained from the TB centres by the NTCP. Confidentiality of the data was prioritised during the data collection period, i.e. the names and registration numbers of the patients were not included in the datasheets. Consent forms were provided and signed by all TB patients before the study began.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"464"}}